Patents by Inventor Michael Voronkov
Michael Voronkov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240131022Abstract: The subject invention pertains to compositions comprising an opioid receptor antagonist and an opioid receptor agonist and methods of inhibiting an opioid overdose in a subject. The opioid receptor antagonist can be naloxone or a derivative thereof, while the opioid receptor agonist can be nalbuphine or a derivative thereof. The composition can be administered intranasally, intravenously and by autoinjector. The reversal time can be about three minutes.Type: ApplicationFiled: June 14, 2023Publication date: April 25, 2024Inventors: John ABERNETHY, Georgiy NIKONOV, Michael VORONKOV
-
Publication number: 20240009184Abstract: The invention presented is a remedial opioid overdose mixture that includes a therapeutically effective dose of an opioid receptor antagonist; and, a therapeutically effective dose of an opioid receptor agonist. In one embodiment, the opioid receptor antagonist is naloxone while the opioid receptor agonist is nalbuphine. One specific naxolone derivative is NX-90 and a specific nalbuphine derivative is NB-33. The mixture can be administered intranasally, intravenously and by autoinjector. In some dose mixtures, reversal time is about three minutes.Type: ApplicationFiled: March 11, 2022Publication date: January 11, 2024Inventors: John Abernethy, Georgiy Nikonov, Michael Voronkov
-
Patent number: 11851439Abstract: The present invention relates to opiate derived compositions and their antagonists useful in therapeutic areas associated with opioid receptor modulation. A 3-hexadienoate modification of the opioids is formulated to improve opiates' engagement of the opioid receptors when given orally. A 3-hexadienoate modification of nalbuphine or a pharmaceutically acceptable salt of thereof to improve quality of pain management when given intravenously, intranasally, transdermally, sublingually, rectally, topically, intramuscularly, subcutaneously or via inhalation. A 3-hexadienoate modification of the opioids antagonists is formulated to improve inhibition of the opioid receptors when given orally. A 3-hexadienoate modification of naloxone or a pharmaceutically acceptable salt of thereof to improve quality of Sobering when given intravenously, intranasally, transdermally, sublingually, rectally, topically, intramuscularly, subcutaneously or via inhalation.Type: GrantFiled: July 1, 2021Date of Patent: December 26, 2023Assignee: Kappa-Pharma LLCInventors: Georgiy Nikonov, Levon Isakulyan, Michael Voronkov
-
Patent number: 11802107Abstract: The present invention provides compounds useful in treating or preventing inflammation, acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.Type: GrantFiled: December 5, 2022Date of Patent: October 31, 2023Assignee: Signum Biosciences, Inc.Inventors: Michael Voronkov, Eduardo Perez, Jason Healy, Jose Fernandez
-
Publication number: 20230174467Abstract: The present invention provides compounds useful in treating or preventing inflammation, acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.Type: ApplicationFiled: December 5, 2022Publication date: June 8, 2023Applicant: Signum Biosciences, Inc.Inventors: Michael Voronkov, Eduardo Perez, Jason Healy, Jose Fernandez
-
Patent number: 11518738Abstract: The present invention provides compounds useful in treating or preventing inflammation, acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.Type: GrantFiled: March 12, 2021Date of Patent: December 6, 2022Assignee: Signum Biosciences, Inc.Inventors: Michael Voronkov, Edwardo Perez, Jason Healy, Jose Fernandez
-
Publication number: 20220257590Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action ?-opioid receptor antagonist/?-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a ?-opioid receptor antagonist or prodrug thereof, and a ?-opioid receptor agonist or prodrug thereof can be administered, either together or separately.Type: ApplicationFiled: April 29, 2022Publication date: August 18, 2022Inventors: M. Maral Mouradian, Steven Braithwaite, Michael Voronkov
-
Publication number: 20210395260Abstract: The present invention relates to opiate derived compositions and their antagonists useful in therapeutic areas associated with opioid receptor modulation. A 3-hexadienoate modification of the opioids is formulated to improve opiates' engagement of the opioid receptors when given orally. A 3-hexadienoate modification of nalbuphine or a pharmaceutically acceptable salt of thereof to improve quality of pain management when given intravenously, intranasally, transdermally, sublingually, rectally, topically, intramuscularly, subcutaneously or via inhalation. A 3-hexadienoate modification of the opioids antagonists is formulated to improve inhibition of the opioid receptors when given orally. A 3-hexadienoate modification of naloxone or a pharmaceutically acceptable salt of thereof to improve quality of Sobering when given intravenously, intranasally, transdermally, sublingually, rectally, topically, intramuscularly, subcutaneously or via inhalation.Type: ApplicationFiled: July 1, 2021Publication date: December 23, 2021Applicant: Kappa-Pharma LLCInventors: Georgiy Nikonov, Levon Isakulyan, Michael Voronkov
-
Patent number: 11186585Abstract: The present invention relates to opiate derived compositions and their antagonists useful in therapeutic areas associated with opioid receptor modulation. A 3-hexadienoate modification of the opioids is formulated to improve opiates' engagement of the opioid receptors when given orally. A 3-hexadienoate modification of Nalbuphine or a pharmaceutically acceptable salt of thereof to improve quality of pain management when given intravenously, intranasally, transdermally, sublingually, rectally, topically, intramuscularly, subcutaneously or via inhalation. A 3-hexadienoate modification of the opioids antagonists is formulated to improve inhibition of the opioid receptors when given orally. A 3-hexadienoate modification of Naloxone or a pharmaceutically acceptable salt of thereof to improve quality of Sobering when given intravenously, intranasally, transdermally, sublingually, rectally, topically, intramuscularly, subcutaneously or via inhalation.Type: GrantFiled: August 14, 2019Date of Patent: November 30, 2021Assignee: Kappa-Pharma LLCInventors: Georgiy Nikonov, Levon Isakulyan, Michael Voronkov
-
Publication number: 20210261499Abstract: The present invention provides compounds useful in treating or preventing inflammation, acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.Type: ApplicationFiled: March 12, 2021Publication date: August 26, 2021Applicant: Signum Biosciences, Inc.Inventors: Michael Voronkov, Edwardo Perez, Jason Healy, Jose Fernandez
-
Patent number: 10975023Abstract: The present invention provides compounds useful in treating or preventing inflammation acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.Type: GrantFiled: January 12, 2018Date of Patent: April 13, 2021Assignee: Signum Biosciences, Inc.Inventors: Michael Voronkov, Edwardo Perez, Jason Healy, Jose Fernandez
-
Patent number: 10912812Abstract: Method of preparing a botanical extract that includes contacting a raw botanical with a solvent having a dielectric constant ranging from about 2.3 to about 25 and allowing the mixture to reside for a sufficient time to obtain a crude extract; filtering out remaining raw botanical and evaporating the solvent from the crude extract under reduced pressure to obtain a dried crude extract; washing the dried crude extract with a polar solvent having a dielectric constant of no less than 30, heating the resulting mixture, and allowing to cool to ambient; collecting a filtrate from the above cooled mixture; washing the collected filtrate with a non-polar solvent having a dielectric constant of no more than 2.0; and filtering and drying the mixture to obtain the botanical extract.Type: GrantFiled: July 17, 2019Date of Patent: February 9, 2021Assignee: Signum Biosciences, Inc.Inventors: Kristen Huber, Michael Voronkov, Jose Fernandez, Karl Rouzard, Eduardo Perez, Maxwell Stock, Jeffry Stock
-
Patent number: 10736889Abstract: Methods of treating patients with dyskinesias, by administering a therapeutically effective amount of a dual-action ?-opioid receptor antagonist/?-opioid receptor agonists or prodrug thereof to a subject in need thereof, sufficient to mitigate the dyskinesia. Alternatively, a combination of both a ?-opioid receptor antagonist or prodrug thereof, and a ?-opioid receptor agonist or prodrug thereof can be administered, either together or separately.Type: GrantFiled: March 1, 2018Date of Patent: August 11, 2020Assignee: Rutgers, The State University of New JerseyInventors: M. Maral Mouradian, Steven Braithwaite, Michael Voronkov
-
Patent number: 10583119Abstract: The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A.Type: GrantFiled: November 8, 2016Date of Patent: March 10, 2020Assignee: Signum Biosciences, Inc.Inventors: Scott Vafai, Michael Voronkov, Maxwell Stock, Jeffry B. Stock, Seung-Yub Lee, Zhu Li, Haoming Gu
-
Publication number: 20200055864Abstract: The present invention relates to opiate derived compositions and their antagonists useful in therapeutic areas associated with opioid receptor modulation, A 3-hexadienoate modification of the opioids is formulated to improve opiates' engagement of the opioid receptors when given orally. A 3-hexadienoate modification of Nalbuphine or a pharmaceutically acceptable salt of thereof to improve quality of pain management when given intravenously, intranasally, transdermally, sublingually, rectally, topically, intramuscularly, subcutaneously or via inhalation. A 3-hexadienoate modification of the opioids antagonists is formulated to improve inhibition of the opioid receptors when given orally. A 3-hexadienoate modification of Naloxone or a pharmaceutically acceptable salt of thereof to improve quality of Sobering when given intravenously, intranasally, transdermally, sublingually, rectally, topically, intramuscularly, subcutaneously or via inhalation.Type: ApplicationFiled: August 14, 2019Publication date: February 20, 2020Applicant: Kappa-Pharma LLCInventors: Georgiy Nikonov, Levon Isakulyan, Michael Voronkov
-
Publication number: 20200017438Abstract: The present invention provides compounds useful in treating or preventing inflammation acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.Type: ApplicationFiled: January 12, 2018Publication date: January 16, 2020Applicant: Signum Biosciences, Inc.Inventors: Michael Voronkov, Edwardo Perez, Jason Healy, Jose Fernandez
-
Publication number: 20190336561Abstract: Compositions containing natural and botanical extracts for use in inhibiting one, two, or three of (a)-(c): (a) demethylation of PP2A by PME-1 methylesterase; (b) formation of free radicals and reactive oxygen species; and/or (c) inflammation. These compositions include an extract of one or more botanicals selected from the group consisting of: juniper berry fruit, schisandra fruit, strawberry fruit, avocado seeds, black raspberry seeds, blueberry seeds, celery seeds, cranberry seeds, fennel seeds, grape seeds, guarana seeds, red raspberry seeds, maca root, goldenseal root, turmeric root, magnolia bark, pygeum bark, red raspberry leaf, almond, cocoa powder, Echinacea angustifolia, prickly pear cactus and walnut.Type: ApplicationFiled: July 17, 2019Publication date: November 7, 2019Applicant: Signum Biosciences, Inc.Inventors: Kristen Huber, Michael Voronkov, Jose Fernandez, Karl Rouzard, Eduardo Perez, Maxwell Stock, Jeffry Stock
-
Patent number: 10314802Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.Type: GrantFiled: August 1, 2017Date of Patent: June 11, 2019Assignee: Signum Biosciences, Inc.Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen, Jinglong Chen
-
Patent number: 10314817Abstract: EHT extract including a mixture of late eluting tryptamides and early eluting tryptamides in a weight ratio of at least about 7:1 late eluting tryptamides:early eluting tryptamides, wherein the EHT extract includes at least 30% eicosanoyl-5-hydroxytryptamide, based on the total weight of the tryptamides in the EHT extract.Type: GrantFiled: October 15, 2015Date of Patent: June 11, 2019Assignee: Signum Biosciences, Inc.Inventors: Jeffry Stock, Maxwell Stock, Michael Voronkov, Jose Fernandez, Kristen Huber
-
Publication number: 20190167619Abstract: A pharmaceutical composition comprising (a) at least one protective agent selected from the group consisting of butylated hydroxyanisole, butylated hydroxytoluene, sodium metabisulfite, tert-butylhydroquinone, methylparaben, propylparaben, benzyl alcohol, poly(acrylic acid), hydroxyethyl cellulose, emulsifying wax, PEG-21 stearyl ether, PEG-2 stearyl ether, white petrolatum, myristyl lactate, diisopropyl adipate, cetyl alcohol, cyclomethicone, oleyl alcohol, cholesterol, and polyoxyethylene(4)lauryl ether; and (b) a therapeutically effective amount of an IPC Active Agent or a pharmaceutically acceptable salt or ester thereof.Type: ApplicationFiled: August 8, 2017Publication date: June 6, 2019Applicant: SIGNUM BIOSCIENCES, INC.Inventors: Michael VORONKOV, Gareth WINCKLE